DPV-001 is under clinical development by UbiVac and currently in Phase I for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 97% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DPV-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DPV-001 overview

DPV-001 (DRibble vaccine) is under development for the treatment of non-small cell lung cancer (NSCLC), head and neck cancer squamous cell carcinoma (HNSCC), recurrent or metastatic advanced prostate adenocarcinoma (metastatic castrate resistant adenocarcinoma), triple negative breast cancer (in combination with OX-40, PD-1 inhibitors), pancreatic cancer (in combination with OX-40, PD-1 inhibitors), breast cancer, gastric cancer, esophageal cancer, colon cancer, ovarian cancer. It is administered as intranodal injection. The vaccine candidate is based on the DRibbles vaccine technology. DRibbles are the short-lived proteins which accumulate as ubiquitin-conjugated proteins and be released from tumor cells as particles. It was also under development for the treatment of mesothelioma, hepatocellular carcinoma and human papillomavirus (HPV) associated cancer.

It was under development for the treatment of bladder cancer (in combination with PD-1/L1 inhibitor).

UbiVac overview

UbiVac LLC (UbiVac) is a clinical stage immuno-oncology companythat offers immunotherapeutic products. The company offers research and development of therapeutic vaccines for the treatment of cancer and infectious diseases. Its pipeline product includes DPV-001, a DC-targeted complex vaccine that is used for the treatment of prostate cancer, breast cancer, bladder and pancreatic cancer. UbiVac’s other products comprise DPV-003 for the treatment of renal and non-small cell lung cancer; DPV-007 for oral cancer and DPV-008 for thyroid cancer. The company’s immunotherapy uses the body’s own immune system to detect and destroy cancer cells. Its therapies and technologies are being tested in preclinical and clinical trials. UbiVac is headquartered in Portland, Oregon, the US.

For a complete picture of DPV-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.